MC
AZN icon

Moors & Cabot’s AstraZeneca AZN Stock Holding History

Moors & Cabot’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
6,886
+50
+0.7% +$9.64K 0.06% 291
2025
Q4 		$1.26M Sell
6,836
-20
-0.3% -$3.51K 0.05% 299
2025
Q3 		$1.05M Buy
6,856
+2,849
+71% +$431K 0.05% 351
2025
Q2 		$560K Sell
4,007
-11
-0.3% -$1.54K 0.03% 479
2025
Q1 		$591K Sell
4,018
-28
-0.7% -$4.05K 0.03% 441
2024
Q4 		$530K Buy
4,046
+450
+13% +$63K 0.03% 489
2024
Q3 		$560K Buy
3,596
+61
+2% +$9.85K 0.03% 470
2024
Q2 		$551K Sell
3,535
-683
-16% -$103K 0.03% 455
2024
Q1 		$571K Buy
4,218
+6
+0.1% +$795 0.03% 456
2023
Q4 		$567K Buy
4,212
+29
+0.7% +$3.77K 0.04% 426
2023
Q3 		$567K Buy
4,183
+170
+4% +$23.2K 0.04% 397
2023
Q2 		$574K Sell
4,013
-1,389
-26% -$204K 0.04% 403
2023
Q1 		$750K Buy
5,402
+21
+0.4% +$2.83K 0.05% 324
2022
Q4 		$730K Buy
5,381
+89
+2% +$11.2K 0.05% 331
2022
Q3 		$580K Sell
5,292
-273
-5% -$34.6K 0.04% 352
2022
Q2 		$735K Buy
5,565
+144
+3% +$18.9K 0.05% 326
2022
Q1 		$719K Buy
5,421
+146
+3% +$17.5K 0.04% 369
2021
Q4 		$614K Buy
5,275
+277
+6% +$32.6K 0.04% 402
2021
Q3 		$600K Sell
4,998
-182
-4% -$21.2K 0.04% 396
2021
Q2 		$621K Sell
5,180
-393
-7% -$43.1K 0.04% 367
2021
Q1 		$554K Sell
5,573
-76
-1% -$7.64K 0.04% 374
2020
Q4 		$563K Buy
5,649
+148
+3% +$15.7K 0.05% 337
2020
Q3 		$603K Sell
5,501
-1,210
-18% -$135K 0.06% 294
2020
Q2 		$706K Sell
6,711
-37
-0.5% -$3.82K 0.08% 244
2020
Q1 		$600K Sell
6,748
-818
-11% -$77K 0.09% 214
2019
Q4 		$756K Buy
7,566
+60
+0.8% +$5.65K 0.08% 243
2019
Q3 		$665K Buy
7,506
+74
+1% +$6.42K 0.07% 263
2019
Q2 		$615K Buy
7,432
+1,392
+23% +$109K 0.08% 259
2019
Q1 		$488K Buy
6,040
+614
+11% +$48.4K 0.07% 283
2018
Q4 		$410K Sell
5,426
-150
-3% -$11.7K 0.06% 291
2018
Q3 		$442K Sell
5,576
-11
-0.2% -$832 0.05% 338
2018
Q2 		$396K Sell
5,587
-671
-11% -$48.3K 0.05% 350
2018
Q1 		$438K Buy
6,258
+70
+1% +$4.85K 0.06% 356
2017
Q4 		$427K Sell
6,188
-1,190
-16% -$80.2K 0.06% 349
2017
Q3 		$501K Sell
7,378
-1,592
-18% -$101K 0.07% 307
2017
Q2 		$610K Buy
8,970
+350
+4% +$22.9K 0.1% 249
2017
Q1 		$533K Buy
8,620
+506
+6% +$29.5K 0.09% 264
2016
Q4 		$441K Buy
8,114
+650
+9% +$36.9K 0.07% 312
2016
Q3 		$492K Buy
7,464
+1,783
+31% +$117K 0.08% 272
2016
Q2 		$340K Sell
5,681
-825
-13% -$47.9K 0.06% 343
2016
Q1 		$364K Buy
6,506
+88
+1% +$5.29K 0.07% 307
2015
Q4 		$438K Buy
6,418
+50
+0.8% +$3.28K 0.08% 278
2015
Q3 		$407K Sell
6,368
-493
-7% -$32.4K 0.08% 294
2015
Q2 		$440K Buy
6,861
+250
+4% +$17.1K 0.07% 299
2015
Q1 		$452K Buy
6,611
+311
+5% +$21.6K 0.08% 287
2014
Q4 		$443K Buy
6,300
+1,550
+33% +$111K 0.08% 287
2014
Q3 		$336K Hold
4,750
– – 0.06% 347
2014
Q2 		$351K Sell
4,750
-700
-13% -$50.6K 0.06% 342
2014
Q1 		$354K Buy
+5,450
New +$352K 0.09% 243

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Moors & Cabot's AZN Position: Q1 2026 in Review

Moors & Cabot increased its AstraZeneca (AZN) stake by 0.73% in Q1 2026, buying an estimated $9.64K and bringing the position to 6,886 shares worth $1.36M. The position accounts for 0.06% of the portfolio, ranked #291.

Moors & Cabot first reported a position in AZN in Q1 2014 and has held it in 49 quarters since. 1,381 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Moors & Cabot held 6,886 shares of AstraZeneca worth $1.36M as of Q1 2026.
  • Moors & Cabot bought 50 AstraZeneca shares in Q1 2026, an estimated $9.64K.
  • AstraZeneca made up 0.06% of Moors & Cabot's portfolio in Q1 2026, its #291 holding.
  • Moors & Cabot first reported a position in AstraZeneca in Q1 2014 and has held it in 49 quarters since.
  • 1,381 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.